Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Clinical Burden and Diagnostic Challenges

Welcome back to another AJMC Payer Perspectives series. In this opening episode titled, ‘Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Clinical Burden and Diagnostic Challenges,’ moderator, Dr. Ryan Haumschild, and panelist, Dr. Kevin Alexander, introduce a discussion focused on the clinical and economic burden of transthyretin amyloid cardiomyopathy (ATTR-CM), with an emphasis on diagnosis, treatment access, and payer considerations.

Dr. Alexander describes ATTR-CM as a progressive systemic disease in which the transthyretin protein misfolds and deposits as amyloid fibrils, primarily in the heart and peripheral nervous system. The condition carries significant morbidity and mortality, with patients experiencing worsening heart failure symptoms, including shortness of breath, leg swelling, and exercise intolerance, along with frequent hospitalizations and functional decline.

A central theme of the discussion is the challenge of timely, accurate diagnosis. Dr. Alexander estimates that only 1 in 4 or 1 in 5 patients with ATTR-CM are currently diagnosed, attributing this to limited historical awareness, a previous reliance on invasive diagnostics like endomyocardial biopsy, and the disease's varied early presentation. Patients often first exhibit orthopedic symptoms, such as carpal tunnel syndrome or bicep tendon tears, years before cardiac involvement becomes apparent, meaning they are more likely to see primary care physicians or orthopedic surgeons than cardiologists.

Both physicians emphasize that diagnostic delays drive repeated hospitalizations and increased costs for patients, health systems, and payers alike, underscoring the importance of multidisciplinary collaboration and earlier identification to improve outcomes and sustainability.

In the next episode titled, ‘Economic Impact and Unmet Needs in ATTR-CM,’ panelists will continue their discussion on ATTR-CM and highlight the primary economic cost drivers of ATTR-CM, emphasizing that diagnostic delays, disease progression, and late-stage healthcare interventions compound costs significantly, while earlier diagnosis and treatment remain critical to improving outcomes and reducing long-term expenditures.